Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
heart transplant
posttransplant malignancy
pretransplant malignancy
prognosis
recurrence
survival
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
29
08
2022
received:
25
04
2022
accepted:
29
08
2022
pubmed:
2
9
2022
medline:
6
12
2022
entrez:
1
9
2022
Statut:
ppublish
Résumé
We aimed to investigate the characteristics and outcomes of HTx recipients with a history of pretransplant malignancy (PTM). Among 1062 HTx recipients between 1997 and 2013, 73 (7.1%) patients had PTMs (77 cancer cases). We analyzed post-HTx outcome, recurrence of PTM, and development of de novo malignancies. Post-HTx outcome included overall survival, 10-year survival, 10-year freedom from cardiac allograft vasculopathy (CAV), non-fatal major adverse cardiac events (NF-MACE), any treated rejection (ATR), acute cellular rejection (ACR), and antibody-mediated rejection (AMR). Four most common PTMs were lymphoproliferative disorders (18.2%), prostate cancers (18.2%), non-melanoma skin cancers (18.2%), and breast cancers (13.0%). Median time from PTM and HTx was 9.0 years. During a median follow-up of 8.6 years after HTx, patients with PTM, compared to those without, showed significantly higher incidence of posttransplant malignancies (43.8% vs. 20.8%, p < .001) including 9.6% (n = 7) of PTM recurrences. However, patients with PTM, compared to those without, showed comparable overall survival, 10-year survival, 10-year freedom from CAV, NF-MACE, ATR, ACR, and AMR. Therefore, a history of PTM should not disqualify patients from HTx listing, while further research is necessary for early detection of posttransplant malignancies in these patients.
Identifiants
pubmed: 36050598
doi: 10.1111/ajt.17186
pii: S1600-6135(23)00045-X
doi:
Substances chimiques
Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2942-2950Informations de copyright
© 2022 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
Kim IC, Youn JC, Kobashigawa JA. The past, present and future of heart transplantation. Korean Circ J. 2018;48(7):565-590.
Lee JH, Kim MS, Yoo BS, et al. KSHF Guidelines for the management of acute heart failure: part II. treatment of acute heart failure. Korean Circ J. 2019;49(1):22-45.
Kim K-J, Cho H-J, Kim M-S, et al. Focused update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure. Int J Heart Fail. 2019;1(1):4-24.
Youn JC, Stehlik J, Wilk AR, et al. Temporal trends of de novo malignancy development after heart transplantation. J Am Coll Cardiol. 2018;71(1):40-49.
Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. Korean J Intern Med. 2019;34(1):11-43.
Kim D, Choi JO, Oh J, et al. The Korean Organ Transplant Registry (KOTRY): second official adult heart transplant report. Korean Circ J. 2019;49(8):724-737.
Chang DH, Youn J-C, Dilibero D, Patel JK, Kobashigawa JA. Heart transplant immunosuppression strategies at cedars-sinai medical center. Int J Heart Fail. 2021;3(1):15-30.
Al-Adra DP, Hammel L, Roberts J, et al. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021;21(2):460-474.
Kobashigawa J, Shah P, Joseph S, et al. Frailty in heart transplantation: Report from the heart workgroup of a consensus conference on frailty. Am J Transplant. 2021;21(2):636-644.
Oubari S, Naser E, Papathanasiou M, et al. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. Eur J Haematol. 2021;107(4):449-457.
Oechslin E, Kiowski W, Schneider J, Follath F, Turina M, Gallino A. Pretransplant malignancy in candidates and posttransplant malignancy in recipients of cardiac transplantation. Ann Oncol. 1996;7(10):1059-1063.
Sigurdardottir V, Bjortuft O, Eiskjaer H, et al. Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. J Heart Lung Transplant. 2012;31(12):1276-1280.
Beaty CA, George TJ, Kilic A, Conte JV, Shah AS. Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation. J Heart Lung Transplant. 2013;32(2):202-211.
Yoosabai A, Mehta A, Kang W, et al. Pretransplant malignancy as a risk factor for posttransplant malignancy after heart transplantation. Transplantation. 2015;99(2):345-350.
Delgado JF, Alonso-Pulpon L, Mirabet S, et al. Cancer incidence in heart transplant recipients with previous neoplasia history. Am J Transplant. 2016;16(5):1569-1578.
Wang YJ, Chiang TY, Hii IH, et al. Outcomes of heart transplant recipients with preexisting malignancies. Transplant Proc. 2018;50(9):2738-2741.
Youn JC, Chung WB, Ezekowitz JA, et al. Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study. Int J Cardiol. 2020;317:167-173.
Chung WB, Youn JC, Youn HJ. Cardiovascular complications of novel anti-cancer immunotherapy: old problems from new agents? Korean Circ J. 2020;50(9):743-753.
Stewart Coats AJ. Common co-morbidities in heart failure - diabetes, functional mitral regurgitation and sleep apnoea. Int J Heart Fail. 2019;1(1):25-41.
Kim I-C, Youn J-C, Lee SE, Jung S-H, Kim J-J. Donor heart utilization in Korea. Int J Heart Fail. 2020;2(4):254-263.
Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1056-1066.
Batra J, DeFilippis EM, Golob S, et al. Impact of pretransplant malignancy on heart transplantation outcomes: contemporary united network for organ sharing analysis amidst evolving cancer therapies. Circ Heart Fail. 2022;15(4):e008968.
Khush KK, Hsich E, Potena L, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report - 2021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1035-1049.
Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35(1):1-23.
Lim WH, Turner RM, Chapman JR, et al. Acute rejection, T-cell-depleting antibodies, and cancer after transplantation. Transplantation. 2014;97(8):817-825.
Ansari D, Lund LH, Stehlik J, et al. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. J Heart Lung Transplant. 2015;34(10):1283-1291.
Rafiei M, Kittleson M, Patel J, et al. Anti-thymocyte gamma-globulin may prevent antibody production after heart transplantation. Transplant Proc. 2014;46(10):3570-3574.
Dillon TA, Sullivan M, Schatzlein MH, et al. Cardiac transplantation in patients with preexisting malignancies. Transplantation. 1991;52(1):82-85.